OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Robert E. Davis, Christoph U. Correll
Expert Review of Neurotherapeutics (2016) Vol. 16, Iss. 6, pp. 601-614
Open Access | Times Cited: 56
Robert E. Davis, Christoph U. Correll
Expert Review of Neurotherapeutics (2016) Vol. 16, Iss. 6, pp. 601-614
Open Access | Times Cited: 56
Showing 26-50 of 56 citing articles:
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, et al.
Schizophrenia Research (2021) Vol. 228, pp. 198-205
Open Access | Times Cited: 23
Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, et al.
Schizophrenia Research (2021) Vol. 228, pp. 198-205
Open Access | Times Cited: 23
Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies
Yuriy M. Kositsyn, Murilo S. de Abreu, Tatiana O. Kolesnikova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9482-9482
Open Access | Times Cited: 7
Yuriy M. Kositsyn, Murilo S. de Abreu, Tatiana O. Kolesnikova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9482-9482
Open Access | Times Cited: 7
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data
Konstantinos Ν. Fountoulakis, Mauricio Tohen, Carlos A. Zarate
European Neuropsychopharmacology (2024) Vol. 81, pp. 1-9
Closed Access | Times Cited: 2
Konstantinos Ν. Fountoulakis, Mauricio Tohen, Carlos A. Zarate
European Neuropsychopharmacology (2024) Vol. 81, pp. 1-9
Closed Access | Times Cited: 2
Synthesis of anti-depressant molecules via metal-catalyzed reactions: a review
Aqsa Kanwal, Uzma Afzal, Muhammad Zubair, et al.
RSC Advances (2024) Vol. 14, Iss. 10, pp. 6948-6971
Open Access | Times Cited: 2
Aqsa Kanwal, Uzma Afzal, Muhammad Zubair, et al.
RSC Advances (2024) Vol. 14, Iss. 10, pp. 6948-6971
Open Access | Times Cited: 2
Metabolic profiling of lumateperone in vitro and in vivo by UPLC-Q Exactive Orbitrap HRMS, and its pharmacokinetic study in rat plasma by LC-MS/MS
Yifan Qiu, Jing Guo, Jindong Chen, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 246, pp. 116221-116221
Closed Access | Times Cited: 2
Yifan Qiu, Jing Guo, Jindong Chen, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 246, pp. 116221-116221
Closed Access | Times Cited: 2
Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?
Leslie Citrome
CNS Spectrums (2016) Vol. 21, Iss. S1, pp. 1-12
Closed Access | Times Cited: 22
Leslie Citrome
CNS Spectrums (2016) Vol. 21, Iss. S1, pp. 1-12
Closed Access | Times Cited: 22
Investigational dopamine antagonists for the treatment of schizophrenia
Sheng‐Min Wang, Hans‐Jürgen Möller, Soo-Jung Lee, et al.
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 6, pp. 687-698
Closed Access | Times Cited: 17
Sheng‐Min Wang, Hans‐Jürgen Möller, Soo-Jung Lee, et al.
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 6, pp. 687-698
Closed Access | Times Cited: 17
Lumateperone for the Treatment of Schizophrenia.
Amber N. Edinoff, Natalie W Wu, Charles deBoisblanc, et al.
Psychopharmacology bulletin (2020) Vol. 50, Iss. 4, pp. 32-59
Closed Access | Times Cited: 15
Amber N. Edinoff, Natalie W Wu, Charles deBoisblanc, et al.
Psychopharmacology bulletin (2020) Vol. 50, Iss. 4, pp. 32-59
Closed Access | Times Cited: 15
Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults
Hagar Abuelazm, Omar H. Elsayed, Rif S. El‐Mallakh
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 8, pp. 751-756
Closed Access | Times Cited: 4
Hagar Abuelazm, Omar H. Elsayed, Rif S. El‐Mallakh
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 8, pp. 751-756
Closed Access | Times Cited: 4
Advances in Mood Disorder Pharmacotherapy: Evaluating New Antipsychotics and Mood Stabilizers for Bipolar Disorder and Schizophrenia
Emilia Kowalczyk, Sylwia Koziej, Ewelina Soroka
Medical Science Monitor (2024) Vol. 30
Open Access | Times Cited: 1
Emilia Kowalczyk, Sylwia Koziej, Ewelina Soroka
Medical Science Monitor (2024) Vol. 30
Open Access | Times Cited: 1
Experimental Serotonergic Agents for the Treatment of Schizophrenia
Enrico Capuzzi, Alice Caldiroli, Veronica Ciscato, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 49-67
Open Access | Times Cited: 10
Enrico Capuzzi, Alice Caldiroli, Veronica Ciscato, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 49-67
Open Access | Times Cited: 10
Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders
Marianna Mazza, Giuseppe Marano, Gianandrea Traversi, et al.
CNS & Neurological Disorders - Drug Targets (2020) Vol. 19, Iss. 4, pp. 243-247
Closed Access | Times Cited: 9
Marianna Mazza, Giuseppe Marano, Gianandrea Traversi, et al.
CNS & Neurological Disorders - Drug Targets (2020) Vol. 19, Iss. 4, pp. 243-247
Closed Access | Times Cited: 9
Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
Rajdip Barman, Pradipta Majumder, Tejaswini Doifode, et al.
World Journal of Psychiatry (2021) Vol. 11, Iss. 12, pp. 1228-1238
Open Access | Times Cited: 9
Rajdip Barman, Pradipta Majumder, Tejaswini Doifode, et al.
World Journal of Psychiatry (2021) Vol. 11, Iss. 12, pp. 1228-1238
Open Access | Times Cited: 9
Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia
Kunal Maini, Janice W. Hollier, Haley Gould, et al.
Health psychology research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Kunal Maini, Janice W. Hollier, Haley Gould, et al.
Health psychology research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Pharmacotherapy and Emerging Treatment Strategies for Schizophrenia
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, et al.
(2023), pp. 149-179
Closed Access | Times Cited: 3
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, et al.
(2023), pp. 149-179
Closed Access | Times Cited: 3
The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence
Kamyar Keramatian, Nellai K. Chithra, Lakshmi N. Yatham
FOCUS The Journal of Lifelong Learning in Psychiatry (2023) Vol. 21, Iss. 4, pp. 344-353
Closed Access | Times Cited: 3
Kamyar Keramatian, Nellai K. Chithra, Lakshmi N. Yatham
FOCUS The Journal of Lifelong Learning in Psychiatry (2023) Vol. 21, Iss. 4, pp. 344-353
Closed Access | Times Cited: 3
Serotonin Receptors for Treatment of Insomnia
Jieon Lee, Hyunah Choo
Chronobiology in Medicine (2019) Vol. 1, Iss. 1, pp. 14-20
Open Access | Times Cited: 4
Jieon Lee, Hyunah Choo
Chronobiology in Medicine (2019) Vol. 1, Iss. 1, pp. 14-20
Open Access | Times Cited: 4
Atypical antipsychotic lumateperone beyond schizophrenia: Seeking clarity in a time of uncertainty
Wael Mohamed
Elsevier eBooks (2024), pp. 461-467
Open Access
Wael Mohamed
Elsevier eBooks (2024), pp. 461-467
Open Access
Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Rafał Jaeschke
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13289-13289
Open Access
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Rafał Jaeschke
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13289-13289
Open Access
Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system
Shengzhu Sun, Ying Zhang, Hong-Yun Wu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access
Shengzhu Sun, Ying Zhang, Hong-Yun Wu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access
New antipsychotic medication
Krzysztof Wojtasik-Bakalarz, Marcin Siwek
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 19-38
Open Access | Times Cited: 1
Krzysztof Wojtasik-Bakalarz, Marcin Siwek
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 19-38
Open Access | Times Cited: 1
Recent Advances in Psychopharmacology
Alexander J. Poznanski, Esther Akinyemi
Advances in Psychiatry and Behavioral Health (2022) Vol. 2, Iss. 1, pp. 253-266
Closed Access | Times Cited: 2
Alexander J. Poznanski, Esther Akinyemi
Advances in Psychiatry and Behavioral Health (2022) Vol. 2, Iss. 1, pp. 253-266
Closed Access | Times Cited: 2
Novel treatment possibilities in depression and schizophrenia
Eva Češková
Psychiatrie pro praxi (2018) Vol. 19, Iss. 2, pp. 53-56
Open Access | Times Cited: 1
Eva Češková
Psychiatrie pro praxi (2018) Vol. 19, Iss. 2, pp. 53-56
Open Access | Times Cited: 1
Lumateperone for major depressive episodes in bipolar I or bipolar II disorder
Meyer
Current psychiatry (2021) Vol. 21, Iss. 3
Open Access | Times Cited: 1
Meyer
Current psychiatry (2021) Vol. 21, Iss. 3
Open Access | Times Cited: 1
Lumateperone in the treatment of psychiatric disorders – a review of the literature
Ada Kaczmarek, Wiktor Szymajda, Katarzyna Dettlaff
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 39-52
Open Access
Ada Kaczmarek, Wiktor Szymajda, Katarzyna Dettlaff
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 39-52
Open Access
